NCT07007052
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07007052
Title Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients (TAGVEN)
Acronym TAGVEN
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors French Innovative Leukemia Organisation
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.